Yield10 Bioscience Valuation

Is YTEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of YTEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate YTEN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate YTEN's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for YTEN?

Key metric: As YTEN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for YTEN. This is calculated by dividing YTEN's market cap by their current revenue.
What is YTEN's PS Ratio?
PS Ratio	0.5x
Sales	US$750.00k
Market Cap	US$363.66k

YTEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.2x
Enterprise Value/EBITDA	-0.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does YTEN's PS Ratio compare to its peers?

The above table shows the PS ratio for YTEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	11.1x
ENDV Endonovo Therapeutics	1.1x	n/a	US$317.5k
BLPH Bellerophon Therapeutics	0.1x	n/a	US$672.8k
CAPS Capstone Holding	0.01x	n/a	US$504.4k
NSTM NovelStem International	43.4x	n/a	US$520.4k
YTEN Yield10 Bioscience	0.5x	n/a	US$363.7k

Price-To-Sales vs Peers: YTEN is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (11.1x).

Price to Sales Ratio vs Industry

How does YTEN's PS Ratio compare vs other companies in the US Biotechs Industry?

129 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	9.7x	21.3%
YTEN Yield10 Bioscience	0.5x	n/a	US$363.66k
GILD Gilead Sciences	4x	2.4%	US$111.86b
BIIB Biogen	2.4x	1.3%	US$23.03b

129 Companies		Estimated Growth	Market Cap
Industry Avg.	9.7x	28.4%
YTEN Yield10 Bioscience	0.5x	n/a	US$363.66k

No more companies

Price-To-Sales vs Industry: YTEN is good value based on its Price-To-Sales Ratio (0.5x) compared to the US Biotechs industry average (9.6x).

Price to Sales Ratio vs Fair Ratio

What is YTEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

YTEN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate YTEN's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

IQVIA Holdings

US$35.9b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

4.7%

-4.8%

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$17.12

4.2%

79.3%